This program provides access to investigational convalescent plasma for hospitalized patients infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.
People who recover from COVID-19 do so, at least in part, because their blood contains substances called antibodies, which are capable of fighting the virus that causes the illness. It turns out that for some other diseases caused by viruses, giving people the liquid portion of blood (plasma), obtained from those who have recovered from the virus, leads to more rapid improvement of the disease.
What we're hoping for
We hope that patients with COVID-19 may improve faster if they receive plasma from those who have recovered from COVID-19, because it may have the ability to fight the virus that causes COVID-19.
ClinicalTrials.gov Identifier: NCT04338360